Fellow's quick read · Rheumatology
Gout
ACR 2020 · reviewed 2026-08-11
Personal study digest for board review. Recommendations are from the cited guideline; the "What's changed since 2020" section is reviewer synthesis of newer evidence, each claim cited. Not a substitute for the full guideline.
In one line
Gout is a treat-to-target disease: start allopurinol low, titrate to serum urate <6 mg/dL, and continue indefinitely. This single principle—now validated by RCT—drives every other decision.
When to start urate-lowering therapy (ULT)
- Strong for ULT in patients with subcutaneous tophi, radiographic damage from gout, or ≥2 flares/year.
- Conditionally for ULT in patients with any prior flare who also have CKD ≥3, serum urate >9 mg/dL, or urolithiasis.
- Conditionally against ULT after a first flare without the modifiers above.
- Conditionally against ULT for asymptomatic hyperuricemia (no flare, no tophi, no stones).
ULT: choice, dosing, and target
| Decision | Recommendation | Strength |
|---|---|---|
| First-line agent | Allopurinol over febuxostat and over probenecid—including in CKD ≥3 | Strong |
| Starting dose | Allopurinol ≤100 mg/day (CKD ≥3: ≤50 mg/day); febuxostat ≤40 mg/day | Strong |
| Titration target | Serum urate <6 mg/dL (treat-to-target); titrate ULT over lab-only monitoring | Strong |
| HLA-B*5801 testing | Test before allopurinol in Southeast Asian descent and African American patients | Conditional |
| Febuxostat + CVD | Switch to an alternative ULT in patients with a history of CVD or a new CV event on febuxostat | Conditional |
| Pegloticase | Reserve for refractory gout (failed adequate trial of xanthine oxidase inhibitors + uricosurics) | Conditional |
| Timing | Conditionally for starting ULT during a flare (over delaying until flare resolves) | Conditional |
| Duration | Strongly against stopping ULT—continue indefinitely | Strong |
Flare management
| Setting | Drug / dose / route | Notes |
|---|---|---|
| Acute flare, first-line | Colchicine, NSAIDs, or glucocorticoids (oral/IA/IM); choose by comorbidities | Strong for any of the three over IL-1 inhibitors or ACTH |
| Colchicine dosing (flare) | Low-dose: 1.2 mg then 0.6 mg one hour later (day 1), then 0.6 mg daily or BID | Per AGREE trial; as effective as high-dose, far fewer GI adverse effects |
| Prophylaxis with ULT initiation | Colchicine 0.6 mg daily or BID (first-line); low-dose NSAID or prednisone ≤10 mg/day as alternatives | Strong for prophylaxis ≥3–6 months (conditionally for >6 months including beyond the target SU) |
Key decisions
- Treat-to-target, not treat-to-dose. The goal is SU <6 mg/dL, not a fixed allopurinol ceiling. Titrate upward (allopurinol well above 300 mg is often needed and safe, even in CKD).
- Allopurinol allergy risk. HLA-B*5801 prevalence is ~6–8% in Southeast Asian and ~3% in African American populations. A positive result is an absolute contraindication to allopurinol (DRESS/SJS-TEN risk).
- Febuxostat and CV risk. CARES (2018) showed higher CV mortality with febuxostat vs allopurinol, triggering an FDA black-box warning. The guideline conditionally recommends switching away from febuxostat in patients with established CVD.
- Concurrent medications. Strongly switch hydrochlorothiazide to an alternative antihypertensive when a substitute is available. Conditionally add or switch to losartan (uricosuric effect).
- Lifestyle. Conditionally limit alcohol and high-purine foods; avoid high-fructose corn syrup. These are adjuncts, not substitutes for pharmacotherapy.
Duration & stopping
- ULT is indefinite. The guideline strongly recommends against stopping ULT in patients who meet the indication.
- Flare prophylaxis: continue for ≥3–6 months after starting ULT, with conditional support for extending beyond 6 months (including beyond achieving target SU) if flares continue.
What's changed since 2020
Reviewer synthesis — not the guideline. Each item cited.
- FAST trial softens febuxostat CV concern. The FAST trial (n=6,128, median 4-year follow-up) found febuxostat non-inferior to allopurinol for the primary MACE composite (HR 0.85, 95% CI 0.70–1.03, on-treatment). Published the same month as the ACR 2020 guideline, so it could not be incorporated. This contradicts the CARES signal and weakens the case for the FDA black-box warning, though a 2026 target-trial emulation (PMID 42535787) still showed modestly higher all-cause mortality with febuxostat in CVD patients (HR 1.125). Net: febuxostat is likely safer than CARES suggested, but cautious use in CVD remains reasonable. FAST: Lancet 2020; PMID 33181081. Target-trial emulation: PMID 42535787.
- Pegloticase + methotrexate: FDA-approved combo (2022). The MIRROR RCT showed co-administration of methotrexate with pegloticase raised the 6-month responder rate from 38.5% to 71% (p<0.0001) and cut infusion reactions from 31% to 4%. The FDA approved pegloticase + MTX coadministration in July 2022. The guideline lists pegloticase as a last-line monotherapy agent; this immunomodulation strategy materially improves its efficacy and tolerability. MIRROR RCT: Arthritis Rheumatol 2022; PMID 36099211.
- Colchicine gains a CV indication. Low-dose colchicine (0.5 mg/day) was approved by the FDA in June 2023 for reducing CV events in established ASCVD, based on LoDoCo2 (31% reduction in primary composite, NEJM 2020) and COLCOT. Relevant because gout patients carry high CV risk and many are already on colchicine for prophylaxis—a dual benefit. The CLEAR trial (2025) found no benefit in acute coronary syndromes, so the indication is chronic stable ASCVD only. LoDoCo2: NEJM 2020; PMID 32865375. COLCOT: NEJM 2019; PMID 31733140.
- GO TEST Overture validates treat-to-target (2026). First pragmatic RCT comparing treat-to-target ULT vs symptom-driven care: 39.4% remission vs 24.0% at 18–24 months (p=0.024). This provides the trial-level evidence the ACR 2020 lacked when making their strong treat-to-target recommendation. Lancet Rheumatol 2026; PMID 41865749.
- HLA-B*5801: universal testing debate. The ACR 2020 guideline conditionally recommends race-based testing (Southeast Asian and African American patients only). Emerging cost-effectiveness data suggest most US racial groups exceed the threshold for routine testing (~1.6% allele prevalence). An ongoing RCT (NCT07369622) is evaluating HLA-B*5801-guided therapy. No guideline change yet, but the practice may shift toward universal pre-allopurinol testing. Open / unresolved.
- No newer ACR or EULAR gout guideline. The 2020 ACR guideline remains current. The most recent EULAR gout recommendations are from 2016; no update has been published. Still current.
Anki cards minted this run
- GO TEST Overture — treat-to-target validation. Q: What 2026 pragmatic RCT validated treat-to-target ULT over symptom-driven care in gout? A: GO TEST Overture — 39.4% vs 24.0% remission at 18–24 months.
- Pegloticase + methotrexate (MIRROR RCT). Q: What immunomodulator co-administered with pegloticase raised the 6-month response rate from 39% to 71%? A: Methotrexate — FDA-approved combo July 2022.
- FAST trial — febuxostat CV safety. Q: What large RCT found febuxostat non-inferior to allopurinol for MACE, contradicting CARES? A: FAST — HR 0.85 (0.70–1.03).
- Allopurinol starting dose in CKD. Q: ACR-recommended starting dose of allopurinol for gout, and how does CKD ≥3 change it? A: ≤100 mg/day (≤50 mg/day in CKD ≥3); titrate to SU <6 regardless of renal function.
Sources
- [1] FitzGerald JD et al. 2020 American College of Rheumatology Guideline for Management of Gout. Arthritis Care Res 2020;72(6):744–760. PMID 32391934. DOI 10.1002/acr.24180.
- [2] Mackenzie IS et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST). Lancet 2020;396:1745–1757. PMID 33181081.
- [3] Botson JK et al. Pegloticase response improvement by co-treatment with methotrexate: results from the MIRROR open-label clinical trial in patients with uncontrolled gout. Arthritis Rheumatol 2022. PMID 36099211.
- [4] Nidorf SM et al. Colchicine in patients with chronic coronary disease (LoDoCo2). N Engl J Med 2020;383:1838–1847. PMID 32865375.
- [5] Tardif J-C et al. Efficacy and safety of low-dose colchicine after myocardial infarction (COLCOT). N Engl J Med 2019;381:2497–2505. PMID 31733140.
- [6] Doherty M et al. Treat-to-target serum urate versus symptom-driven care in gout (GO TEST Overture). Lancet Rheumatol 2026. PMID 41865749.
- [7] White WB et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout (CARES). N Engl J Med 2018;378:1200–1210. PMID 29527974.
- [8] Febuxostat target-trial emulation in CVD patients. 2026. PMID 42535787.